Loews Corporation quietly compounds value through share buybacks, insurance income, and disciplined capital allocation, all ...

The head of Enbridge Inc. says he's encouraged by conversations in both Canada and the U.S. on building more energy ...

Agios Pharmaceuticals gears up for a pivotal 2025 with key PYRUKYND milestones, including FDA decisions for thalassemia.

Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

Canada needs more options to get its energy to new markets. This TSX dividend stock is in a prime position to prosper in the coming years.